CLEO DIAGNOSTICS LTD - News & Media

Market Cap $26.11M Add to my watchlist

Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal... Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. It focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. It is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. It has developed a three-phased product development strategy that delivers three related tests for ovarian cancer detection: Triage Test, Recurrence Test, and Screening Test. Triage Test is a pre-surgical test to determine the likelihood that a pre-surgical ovarian mass in a patient not yet referred to an oncologist, is malignant.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Articles & Videos

Cleo kicks off long path towards FDA approval for ovarian cancer blood tests

Cleo Diagnostics has announced it's commenced the FDA regulatory process to get into the US market with its ovarian cancer test kit.

26 Jun 2024 09:55 (AEST)

Cleo Diagnostics reports its ovarian cancer blood tests superior to ultrasound

Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.The company @ developing a blood test to detect ovarian cancer as opposed to relying on ultrasound @ has declared its blood tests detected 90% of early-stage cancers in participating pati...

29 May 2024 10:36 (AEST)

Early-stage ovarian cancer researcher Cleo Diagnostics (ASX:COV) makes ASX debut after $12m IPO

Early-stage ovarian cancer researcher Cleo Diagnostics is making its ASX debut today following an IPO where it raised $12 million.

22 Aug 2023 14:59 (AEST)

(20min delay)
Last 32.0¢		Change -0.015(4.48%)		Mkt cap ! $26.11M

Open	High	Low	Value	Volume
32.5¢	32.5¢	31.0¢	$70.84K	222.8K

Buyers (Bids)

No.	Vol.	Price($)
1	10000	31.5¢

Sellers (Offers)

Price($)	Vol.	No.
34.0¢	29329	2

View Market Depth

No.	Vol.	Price($)
1	10000	0.315
3	19128	0.310
3	41569	0.305
5	68249	0.300
1	26685	0.295

Price($)	Vol.	No.
0.340	29329	2
0.370	26664	1
0.380	20212	1
0.390	27129	1
0.395	15000	1

Last trade - 15.00pm 22/07/2024 (20 minute delay)


Last 32.0¢		Change -0.015 ( 4.48 %)
Open	High	Low	Volume
32.0¢	32.0¢	31.5¢	10992
Last updated 10.46am 22/07/2024 ?

COV (ASX) Chart